RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Clear Cell Renal Carcinoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Glut1 and MCT4 cooperatively promote ccRCC cell proliferation and are associated with glycolytic reprogramming and immune-related alterations.
Cui Kun et al., Biochemical and biophysical research communications (22 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42732652/
- 2.
Restricted mean survival time-based network meta-analysis of first-line therapies for metastatic clear cell renal cell carcinoma.
McGrath Joseph et al., Urologic oncology (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42892578/
- 3.
CDHR5 and UPB1 expression associated with promoter methylation in sarcomatoid differentiated clear cell renal cell carcinoma
Fernanda Fernandes‐Pontes et al., Epigenetics Communications (16 October 2026)
https://doi.org/10.1186/s43682-026-00053-7
- 4.
Integrated network toxicology, transcriptomic, and Mendelian randomization analyses explore potential molecular links between acrylamide exposure and clear cell renal cell carcinoma.
Deng Shuwen et al., Medicine (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42888631/
- 5.
Integrated multi‑dataset analysis identifies ADH6, ALDOC, PHKA2, and PNMA2 as novel candidate biomarkers for clear cell renal cell carcinoma
Qifan Chen et al., Discover Oncology (15 October 2026)
https://doi.org/10.1007/s12672-026-06115-5
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Imaging Study in Metastatic Clear Cell RCC.
NCT07671417 · Recruiting · Early Phase 1 · RayzeBio, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT07671417
- 2.
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
NCT07197580 · Recruiting · Phase 3 · Telix Pharmaceuticals (Innovations) Pty Limited
Ages 18 and over
https://clinicaltrials.gov/study/NCT07197580
- 3.
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415 · Recruiting · Phase 1 / Phase 2 · Pfizer
Ages 18 and over
https://clinicaltrials.gov/study/NCT07227415
- 4.
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719 · Recruiting · Phase 3 · Arcus Biosciences, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT07011719
- 5.
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 · Recruiting · Phase 1 · MacroGenics
Ages 18 and over
https://clinicaltrials.gov/study/NCT06242470
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Clear Cell Renal Carcinoma
Clear cell renal carcinoma is a cancer that begins in the lining of the small tubes of the kidney, named for the pale appearance of the tumour cells under a microscope. It may cause blood in the urine, flank pain or no symptoms at all, and is often found by chance on a scan. Treatment can include surgery to remove part or all of the kidney, ablation, targeted therapies and immunotherapy, with regular follow-up imaging.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Clear cell renal cell carcinoma (ccRCC) is characterized by glycolytic reprogramming and a lactate-rich tumor microenvironment. We integrated multi-omics, single-cell, tissue microarray, and in vitro analyses to investigate the roles of Glut1 and MCT4 in ccRCC. Both transporters were upregulated at the mRNA and protein levels, enriched in tumor epithelial cells, and located within a glycolysis-associated co-expression module. Elevated MCT4 expression and combined Glut1/MCT4 dysregulation were associated with poor overall survival, while a glycolysis-related random forest model improved prognostic prediction. Functionally, Glut1 and MCT4 exhibited reciprocal expression changes and promoted cell proliferation and cell-cycle progression. Combined knockdown produced a greater inhibitory effect than either individual knockdown in both 786-O and Caki-1 cells. Computational analyses further associated Glut1/MCT4 expression with immune-related features and predicted immunotherapy response, whereas metabolomics revealed elevated lactate and ribose 5-phosphate levels. Collectively, these findings identify a coordinated Glut1-MCT4 axis associated with proliferative, metabolic, prognostic, and immune-related features in ccRCC, although further mechanistic and in vivo validation is required.
Common Questions
What is Clear Cell Renal Carcinoma?
Clear cell renal carcinoma is a cancer that begins in the lining of the small tubes of the kidney, named for the pale appearance of the tumour cells under a microscope. It may cause blood in the urine, flank pain or no symptoms at all, and is often found by chance on a scan. Treatment can include surgery to remove part or all of the kidney, ablation, targeted therapies and immunotherapy, with regular follow-up imaging.
How many clinical trials are available for Clear Cell Renal Carcinoma?
RareWays currently indexes 283 clinical trials for Clear Cell Renal Carcinoma, of which 73 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Clear Cell Renal Carcinoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Clear Cell Renal Carcinoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.